Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

Blood. 2023 Mar 23;141(12):1489-1493. doi: 10.1182/blood.2022016678.

Amanda Przespolewski¹, Aaron D Goldberg², Chetasi Talati^{3

4}, Salman Fazal⁵, Pankit Vachhani⁶, Srinivasa R Sanikommu⁷, Swapna Thota^{1

8}, Julian Waksal^{2

9}, Brian Ball^{2

10}, Christopher Famulare², Maximilian Stahl^{2

11}, Jeffrey Baron¹², Elizabeth A Griffiths¹, James E Thompson¹, Kendra Sweet³, Eunice S Wang¹

¹ Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
² Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY.
³ Moffitt Cancer Center, Tampa, FL.
⁴ AbbVie Inc, North Chicago, IL.
⁵ Allegheny Health Network, Pittsburgh, PA.
⁶ O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL.
⁷ Levine Cancer Institute, Charlotte, NC.
⁸ The University of Tennessee Health Science Center, Memphis, TN.
⁹ Department of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.
¹⁰ Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope Cancer Center, Duarte, CA.
¹¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
¹² Department of Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, NY.

No abstract available

Publication types